Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Research Paper from Dr. Lilge

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Sep 10, 2021 10:58pm

191 Views

Post# 33844465

RE:RE:New Research Paper from Dr. Lilge

Actually, that presentation does not take "Breakthrough Designation" and the following "Accelerated Approval" into account. It is under-promising with a mind to over-deliver, IMO. And that works for me.

VentureGuy24 wrote: "It can't do this without help, but the kind of help needed is not going to come until it has been proven that pdt with TLD1433 is a safe and very effective treatment of BCG refractory NMIBC. And for that we have to wait until 2023. Meanwhile millions of people die of cancer every year. All we can do is wait and hope"

Updated presentation states commercialization in 2025. Doubt 2023 as you mention. And that assumes everything goes smoothly with no obstacles in between.